Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Santilli

Showing results (31-40 of 149) with videos related to

Pageof 15
Sort By:
European Journal of Internal Medicine|June 17, 2025
Addressing unmet needs in the use of SGLT2 inhibitors in critical and acute care settingDamiano D'Ardes, Fabrizio Ricci, Paola Simeone, et al.
American Journal of Preventive Cardiology|January 12, 2023
Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implicationsMichael J Blaha, Magdy Abdelhamid, Francesca Santilli, et al.
British Journal of Haematology|March 21, 2009
Soluble CD40 ligand and endothelial dysfunction in aspirin-treated polycythaemia vera patientsGianfranco Lessiani, Alfredo Dragani, Angela Falco, et al.
International Journal of Molecular Sciences|June 18, 2020
Prion Protein in Stem Cells: A Lipid Raft Component Involved in the Cellular Differentiation ProcessStefano Martellucci, Costantino Santacroce, Francesca Santilli, et al.
Thrombosis and Haemostasis|April 8, 2009
Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirinCaterina Pettinella, Mario Romano, Liborio Stuppia, et al.
Annals of Medicine|June 30, 2023
Is there a rationale for supplementing with vitamin D patients under treatment with allergen immunotherapy?Mario Di Gioacchino, Claudia Petrarca, Loredana Della Valle, et al.
American Journal of Preventive Cardiology|May 2, 2024
Needs-based considerations for the role of low-dose aspirin along the CV risk continuumFrancesca Santilli, Gerhard Albrecht, Michael Blaha, et al.
Thrombosis and Haemostasis|May 14, 2016
Microparticles as new markers of cardiovascular risk in diabetes and beyondFrancesca Santilli, Marco Marchisio, Paola Lanuti, et al.
Stem Cell Reviews and Reports|April 8, 2021
Regenerative Potential of DPSCs and Revascularization: Direct, Paracrine or Autocrine Effect?Vincenzo Mattei, Stefano Martellucci, Fanny Pulcini, et al.
American Journal of Preventive Cardiology|June 27, 2022
Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular diseaseXiao-Ying Li, Li Li, Sang-Hoon Na, et al.
Pageof 15

Showing results (31-40 of 149) with videos related to

Sort By:
Pageof 15
European Journal of Internal Medicine|June 17, 2025
Addressing unmet needs in the use of SGLT2 inhibitors in critical and acute care settingDamiano D'Ardes, Fabrizio Ricci, Paola Simeone, et al.
American Journal of Preventive Cardiology|January 12, 2023
Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implicationsMichael J Blaha, Magdy Abdelhamid, Francesca Santilli, et al.
British Journal of Haematology|March 21, 2009
Soluble CD40 ligand and endothelial dysfunction in aspirin-treated polycythaemia vera patientsGianfranco Lessiani, Alfredo Dragani, Angela Falco, et al.
International Journal of Molecular Sciences|June 18, 2020
Prion Protein in Stem Cells: A Lipid Raft Component Involved in the Cellular Differentiation ProcessStefano Martellucci, Costantino Santacroce, Francesca Santilli, et al.
Thrombosis and Haemostasis|April 8, 2009
Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirinCaterina Pettinella, Mario Romano, Liborio Stuppia, et al.
Annals of Medicine|June 30, 2023
Is there a rationale for supplementing with vitamin D patients under treatment with allergen immunotherapy?Mario Di Gioacchino, Claudia Petrarca, Loredana Della Valle, et al.
American Journal of Preventive Cardiology|May 2, 2024
Needs-based considerations for the role of low-dose aspirin along the CV risk continuumFrancesca Santilli, Gerhard Albrecht, Michael Blaha, et al.
Thrombosis and Haemostasis|May 14, 2016
Microparticles as new markers of cardiovascular risk in diabetes and beyondFrancesca Santilli, Marco Marchisio, Paola Lanuti, et al.
Stem Cell Reviews and Reports|April 8, 2021
Regenerative Potential of DPSCs and Revascularization: Direct, Paracrine or Autocrine Effect?Vincenzo Mattei, Stefano Martellucci, Fanny Pulcini, et al.
American Journal of Preventive Cardiology|June 27, 2022
Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular diseaseXiao-Ying Li, Li Li, Sang-Hoon Na, et al.
Pageof 15